In responding to the Therapeutic Goods Administration’s (TGA) interim decision in relation to cannabidiol (CBD) to down-schedule CBD medicines to S3, or pharmacist-only, medicines at appropriate dosage levels, Medicinal Cannabis Industry Australia (MCIA) has recommended further change to the proposed scheduling to ensure that there is an effective pathway for S3 CBD products.
Medicinal cannabis has an important role to play in improving health outcomes. MCIA supports down- scheduling of CBD to S3, which has the potential to provide patients with improved access to a safe low dose cannabis product for medical use.
Continue reading “MCIA pursues better patient access for down scheduled CBD”